The business scope of the company is to produce small-volume injections, tablets, hard capsules, granules and raw materials; Chinese medicine extraction; Research, development, consultation and service of bioengineering drugs, genetic engineering drugs and phytochemicals; Ordinary freight. The company is a high-tech enterprise jointly recognized by Tianjin Science and Technology Commission, Tianjin Finance Bureau, Tianjin State Taxation Bureau and Tianjin Local Taxation Bureau. He owns 8 patents (including 3 invention patents), has accepted 5 invention patents, applied for 4 scientific research projects of Ministry of Science and Technology, 7 scientific research projects of National Development and Reform Commission, Tianjin Development and Reform Commission/KLOC-0 and Tianjin Science and Technology Commission. The company has 8 national new drug certificates and 22 drug approval documents, and all dosage forms production workshops have passed GMP certification.
The company is mainly engaged in the research, development, production and sales of Chinese patent medicines and western medicines. Its leading products include Xuebijing injection and Fasudil hydrochloride injection. Xuebijing injection is the only national second-class new drug approved by SFDA to treat sepsis and multiple organ dysfunction syndrome in China, with clear treatment mechanism and remarkable treatment effect, and has a monopoly position in the market segment; The company owns the independent intellectual property rights of the drug and two national invention patents; The research, development and industrialization of the drug were supported by the National Development and Reform Commission's "National Investment Plan for High-tech Industry Development" and the Ministry of Science and Technology's "Innovation Fund Project for Small and Medium-sized Sci-tech Enterprises". It won the first prize of Tianjin Excellent Technological Innovation Project in 2006, the second prize of Science and Technology Award issued by China Association of Integrated Traditional Chinese and Western Medicine, the second prize of Tianjin Patent Excellence Award in 2007 and the second prize of Tianjin Scientific and Technological Progress Award in 2008. In May 2006, it was jointly recognized as a "secret" by the Ministry of Science and Technology and In 2009, it was selected as a Chinese medicine treatment drug based on syndrome differentiation by the Ministry of Health's "Influenza A H 1N 1 Diagnosis and Treatment Plan (second edition trial in 2009)".
Fasudil hydrochloride injection is a national second-class new drug and the only Rho kinase inhibitor listed in China. Our company is the only enterprise that produces this kind of raw materials and injections in China, and the new drug has a four-year transition period. The research, development and industrialization of the drug have been supported by the Innovation Fund for Small and Medium-sized Sci-tech Enterprises of the Ministry of Science and Technology and the Achievement Appraisal Project of Scientific and Technological Achievements Transformation Project of Tianjin Science and Technology Commission. And won the first prize of Tianjin excellent technological innovation project in 2007 and the second prize of Tianjin scientific and technological progress in 2008. The drug was in a monopoly position among similar products in the industry in 2008, with a market share of 97.40% in 2008. The market share of cerebral vasospasm chemicals is 44.93%, ranking first.
The company has always adhered to the concept of "pursuing excellent quality and creating a healthy life". From 2006 to 2009, with the promotion of targeted academic marketing, the company has made remarkable achievements. In addition, the company did not forget to repay the society, and made many donations and materials, which gained a good reputation and was widely recognized by all sectors of society.
On June 30th, 2009, 10, the company was officially listed on the Growth Enterprise Market of Shenzhen Stock Exchange, which is undoubtedly a development opportunity for the company. In the future, the company will comprehensively improve the company's new drug research and development capabilities, production capacity, operational efficiency, market share and profitability through technological innovation, management innovation, professional academic promotion and fund-raising project construction, thus consolidating and improving the company's core competitiveness.